UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
SCHEDULE 13D
(Amendment No. 3)
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Quest Diagnostics Incorporated
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, $.01 Par Value
--------------------------------------------------------------------------------
(Title of Class of Securities)
74834L 10 0
--------------------------------------------------------------------------------
(CUSIP Number)
Donald F. Parman, GlaxoSmithKline
One Franklin Plaza, Philadelphia, PA 19102
Telephone 215-751-7633
--------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person Authorized to
Receive Notices and Communications)
June 25, 2004
--------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box / /.
Check the following box if a fee is being paid with the statement / /. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7.)
Note: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
This Amendment No. 3 amends and supplements the Statement of Schedule 13D
electronically filed with the Securities and Exchange Commission (the
"Commission") on August 25, 1999 (the "Initial Statement"), and subsequent
amendments filed electronically with the Commission on May 14, 2001 and May 22,
2002.
The undersigned hereby amends and supplements Items 2 and 5 of the Initial
Statement to include the following information (capitalized terms used herein
without definition shall have the same meaning as set forth in the Initial
Statement).
SCHEDULE 13D
CUSIP NO. 74834L100
--------------------------------------------------------------------------------
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
GlaxoSmithKline plc
-------------------------------------------------------------------------------
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) / /
(b) / /
--------------------------------------------------------------------------------
3 SEC USE ONLY
--------------------------------------------------------------------------------
4 SOURCE OF FUNDS*
OO
--------------------------------------------------------------------------------
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(D) OR 2(E) / /
--------------------------------------------------------------------------------
6 CITIZENSHIP OR PLACE OF ORGANIZATION
England and Wales
--------------------------------------------------------------------------------
7 SOLE VOTING POWER
NUMBER OF
SHARES
BENEFICIALLY -----------------------------------------------------------------
OWNED BY 8 SHARED VOTING POWER
EACH
REPORTING 20,952,154
PERSON -----------------------------------------------------------------
WITH 9 SOLE DISPOSITIVE POWER
-----------------------------------------------------------------
10 SHARED DISPOSITIVE POWER
20,952,154
--------------------------------------------------------------------------------
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
20,952,154
--------------------------------------------------------------------------------
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES
CERTAIN SHARES* / /
--------------------------------------------------------------------------------
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
20.5%
--------------------------------------------------------------------------------
14 TYPE OF REPORTING PERSON*
CO
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
Item 1. Security and Issuer.
Item 2. Identity and Background.
(a)
(b)
(c) Set forth in Schedule I to this Amendment ("Schedule I") are the
names, business address and present principal occupation or employment of each
executive officer and director of the Company.
(d) During the last five years, there have been no criminal proceedings
against the Company or, to the best knowledge of the Company, any of the other
persons with respect to whom information is given in response to this Item 2.
(e) During the last five years, neither the Company nor, to
the best knowledge of the Company, any of the other persons with respect to whom
information is given in response to this Item 2 has not been a party to any
civil proceeding of a judicial or administrative body of competent jurisdiction
resulting in a judgment, decree or final order enjoining future violations of,
or prohibiting or mandating activities subject to Federal or State securities
laws or finding any violation with respect to such laws.
(f) The citizenship of each executive officer and director of the
Company is set forth in Schedule I.
Item 3. Source and Amount of Funds or Other Consideration.
Item 4. Purpose of Transaction.
Item 5. Interest in Securities of the Issuer.
(a) Amount and Percent Beneficially Owned
Registered Name No. of Shares Percent
SmithKline Beecham Corporation 20,952,154 20.5%
(b)
(c) On June 25, 2004, the Company sold 1,176,518 shares to the
Issuer for $86.13 per share.
(d)
(e)
Item 6. Contracts, Arrangements, Understandings or
Relationship With respect to Securities of the Issuer.
Item 7. Materials to be Filed as Exhibits.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
the undersigned certifies that the information set forth in the Statement is
true, correct and complete.
DATED: June 29, 2004 GLAXOSMITHKLINE PLC
By:
S.M. BICKNELL
Company Secretary
SCHEDULE I
Principal
Occupation
Name Business Address or Employment Citizenship
Board of Directors
Dr. Jean-Pierre Garnier One Franklin Plaza Chief Executive French/USA
Philadelphia, PA Officer
19102
John D. Coombe 980 Great West Road Chief Financial British
Brentford Officer
Middlesex
England TW8 9GS
Dr. Tadataka Yamada 709 Swedeland Road Executive Director USA
King of Prussia, PA Chairman Research
19406 and Development
Sir Christopher Hogg Reuters Holdings plc Company Director British
85 Fleet Street
London, England
EC4P 4AJ
Sir Crispin Davis Reed Elsevier Group Company Director British
plc
1-3 Strand
London, England
WC2N 5JR
Sir Peter Job 980 Great West Road Company Director British
Brentford
Middlesex
England
TW8 9GS
Sir Ian Prosser 980 Great West Road Company Director British
Brentford
Middlesex
England, TW8 9GS
Dr. Lucy Shapiro Stanford University Company Director USA
School of Medicine
Beckman Center, B300
279 Campus Drive
Stanford, California
94305-5329
Lawrence Culp Danaher Corporation Company Director USA
2099 Pennsylvania
Avenue, 12th Floor,
Washington DC20006
Sir Christopher Gent 980 Great West Road Company Director British
Brentford
Middlesex
England, TW8 9GS
Sir Deryck Maughan Citigroup Company Director British
399 Park Avenue
New York
NY 10022
Dr. Ronaldo Schmitz Deutsche Bank Company Director German
Taununsanlage 12
D-62062 Frankfurt
Germany
Sir Robert Wilson 24 Edwards Square Company Director British
London
England, W8 6HH
GlaxoSmithKline
Corporate Executive Team
Dr. Jean-Pierre Garnier One Franklin Plaza Chief Executive French/USA
Philadelphia, PA Officer
19102
John D. Coombe 980 Great West Road Chief Financial British
Brentford Officer
Middlesex
England TW8 9GS
Rupert M. Bondy 980 Great West Road Senior Vice British
Brentford President and
Middlesex General Counsel
England TW8 9GS
Ford Calhoun One Franklin Plaza Chief Information USA
Philadelphia, PA Officer
19102
Marc Dunoyer GSK Building President French
6-15, Sendagaya Pharmaceuticals
4 chome,Shibuya-ku Japan
Tokyo 151-8566
Russell Greig 980 Great West Road President British
Brentford Pharmaceuticals
Middlesex International
England, TW8 9GS
Daniel J. Phelan One Franklin Plaza Senior Vice USA
Philadelphia, PA President
19102 Human Resources
David Pulman Five Moore Drive President British
PO Box 13398 Global Manufacturing
Research Triangle & Supply
Park, North Carolina
27709
David M. Stout One Franklin Plaza President USA
Philadelphia, PA Pharmaceutical
19102 Operations
Christopher Viehbacher Five Moore Drive President German/
PO Box 13398 US Pharmaceuticals Canadian
Research Triangle Park
North Carolina 27709
Andrew Witty 980 Great West Road President British
Brentford Pharmaceuticals
Middlesex Euorpe
England, TW8 9GS
Dr. Tadataka Yamada 709 Swedeland Road Executive Director USA
King of Prussia, PA Chairman Research
19406 and Development
Jennie Younger 980 Great West Road Senior Vice British
Brentford President Corporate
Middlesex Communications &
England, TW8 9GS Community Partnerships
Jack Ziegler One Franklin Plaza President USA
Philadelphia, PA Consumer Healthcare
19102